Infinity Pharmaceuticals, Inc. (INFI) Misses Q4 EPS by 11c; Issues FY12 Loss Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts INFI Hot Sheet
Join SI Premium – FREE
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported Q4 EPS of ($0.53), $0.11 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $0 versus the consensus estimate of $23.77 million.
Infinity Pharmaceuticals, Inc. sees FY2012 EPS of $-1.30-$-1.70, versus the consensus of $-1.46.
For earnings history and earnings-related data on Infinity Pharmaceuticals, Inc. (INFI) click here.
Infinity Pharmaceuticals, Inc. sees FY2012 EPS of $-1.30-$-1.70, versus the consensus of $-1.46.
For earnings history and earnings-related data on Infinity Pharmaceuticals, Inc. (INFI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H2O America (HTO) Misses Q3 EPS by 16c ; Offers Guidance
- Park National Corp. (PRK) Tops Q3 EPS by 6c
- JetBlue shares jump on Q3 results and 2027 outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
